Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653912 | 0.92 | FLT3 (0.71) | FLT3CHEK2NPC1 | |
| SCHEMBL5651447 | 0.86 | FLT3 (0.62) | FLT3THRB | |
| SCHEMBL5651512 | 0.86 | FLT3 (0.62) | FLT3THRB | |
| SCHEMBL5649766 | 0.86 | FLT3 (0.62) | FLT3THRB | |
| SCHEMBL5649663 | 0.85 | FLT3 (0.61) | FLT3CDK2IKBKEAURKBTBK1 | |
| SCHEMBL5652034 | 0.84 | FLT3 (0.58) | FLT3CHEK2 | |
| SCHEMBL5651531 | 0.83 | FLT3 (0.58) | FLT3 | |
| SCHEMBL21017244 | 0.83 | CHEK2 (0.61) | FLT3CHEK2 | |
| SCHEMBL21018109 | 0.83 | FLT3 (0.54) | FLT3CHEK2NPC1RAB9A | |
| SCHEMBL5653663 | 0.82 | KDM4E (0.57) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885CHEK2 4002/4885CDK2 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.